10-K · February 25, 2026
LivaNova reported full-year 2025 net revenue of $1,388,053,000, up 10.7% from $1,253,437,000 in 2024, with operating income rising to $199,390,000 (14.4% operating margin) from $129,051,000 (10.3%). The company…
Earnings analysis · 10-Q
LIVN earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
LivaNova reported Q1 2026 revenue of $362.3 million, exceeding estimates of $346.8 million by 4.3%, while EPS of $0.40 missed expectations of $0.86. The company increased its full-year 2026 revenue guidance to a growth…
Read full summary
LivaNova reported Q1 2026 revenue of $362.3 million, exceeding estimates of $346.8 million by 4.3%, while EPS of $0.40 missed expectations of $0.86. The company increased its full-year 2026 revenue guidance to a growth range of 7% to 8%, reflecting strong performance in the Cardiopulmonary segment, which experienced an 18.3% revenue increase. However, operating margins remained challenged with fluctuating figures.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.4
- Operating margin
- 11.5%
What stood out
-
Revenue Exceeds Estimates
Q1 2026 revenue was $362.3 million, 4.3% higher than the estimated $346.8 million.
-
Cardiopulmonary Segment Growth
The Cardiopulmonary segment saw an 18.3% revenue increase, significantly contributing to total revenues.
-
Adjusted EPS Guidance Raised
The adjusted EPS guidance was increased to $4.20 - $4.30, up from the previous range of $4.15 - $4.25.
-
Improved Free Cash Flow
Free cash flow reached $15.2 million, indicating cash generation capabilities.
-
Operating Margin Recovery Signs
Operating margin improved to 11.5% from a prior negative margin of -98.2% in Q1 2025.
-
Full-Year Revenue Guidance Increased
Full-year 2026 revenue guidance was raised to a growth range of 7% to 8%.
What to watch
-
Previous High Losses Affecting Sentiment
LivaNova reported a diluted EPS of -6.01 for Q1 2025, indicating significant losses from the prior year.
-
Regulatory and Legal Risks Persist
The company remains exposed to regulatory risks associated with its operations and past legal proceedings.
-
Ongoing Market Risks and Foreign Operations Exposure
LivaNova's operations are exposed to foreign currency exchange risks, as noted in their risk management disclosures.
Management's outlook
Revenue guidance increased to 7-8% growth, EPS adjusted to $4.20-$4.30.
Earlier filings 4
10-Q · August 6, 2025
LivaNova reported a strong operational quarter with net revenue of $352,524,000, up 10.7% year-over-year, and operating income of $54,183,000 (15.4% operating margin) driving diluted EPS of $0.50 (vs $0.30 prior year).…
10-Q · May 7, 2025
LivaNova reported Q1 net revenue of $316,855,000, up 7.4% year-over-year, with gross profit of $220,775,000 (69.7% gross margin) and operating income improving to $48,617,000. The quarter produced a large, one-time…
10-Q · August 1, 2024
LivaNova reported Q2 net revenue of $318.6M, up 8.4% year-over-year, with gross profit of $218.9M and operating income of $40.2M for the quarter. The quarter delivered diluted EPS of $0.30 and materially stronger…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.